2011
Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure
Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure. Proteomics Clinical Applications 2011, 5: 193-193. DOI: 10.1002/prca.201190010.Peer-Reviewed Original Research
2009
Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure.
Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure. Cancer Research 2009, 69: 2037-2037. DOI: 10.1158/0008-5472.sabcs-09-2037.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHER2-positive breast cancerResponse groupPre-surgery samplesPathological complete responseBreast cancer patientsRandomized clinical trialsPreoperative chemotherapyComplete responsePlasma protein profileResidual diseaseCancer patientsTumor responseClinical trialsBreast cancerTumor markersChemotherapySerum profileBaseline samplesCancer ResPatientsRD groupEvaluation of changesP componentProtein profiles